Jagadish Gogate, PhD

Adverse Events Affecting Readiness for Discharge From the Clinical Setting After Esketamine Nasal Spray Administration

Objective: To describe clinical findings in patients considered not ready for discharge from clinical sites 2 hours after administration of esketamine nasal spray (ESK).

Leah Aluisio , PhD;

David Williamson , PhD, MBA;

Ella Daly , MB, BCh, BAO;

Michelle Han , PharmD;

Sheldon Preskorn , MD;

Jagadish Gogate , PhD;

H. Lynn Starr , MD, FAAP;

Andrew Winokur , MD, PhD;

11/22/2019

Withdrawal Symptom Assessment in an Esketamine Safety Study in Patients With Treatment-Resistant Depression in SUSTAIN-2 (NCT02497287)

We assessed potential withdrawal symptoms in patients with treatment-resistant depression (TRD) after long-term, intermittent use of intranasal esketamine (ESK). Patients received ESK 2X/...

Allitia DiBernardo , MD;

Ewa Wajs , MD, PhD;

Andrew Krystal , MD;

Lynn Yieh , PhD;

Ella Daly , MB, BCh, BAO;

Leah Aluisio , PhD;

Wayne Drevets , MD;

Yun Wu , PhD;

Jaskaran Singh , MD;

Peter Zannikos , PhD;

Jagadish Gogate , PhD;

Valerie Curran , PhD;

Guang Chen , MD, PhD;

11/22/2019

Relationship Between Improved Caregiver Burden and Associated Clinical Improvement in Schizophrenia Patients Treated With Paliperidone Palmitate

Objective: Burden is significant for caregivers of patients with schizophrenia. Little is known about the relationship between changes in patient illness severity and functioning and chan...

Kristy Tardieu , BSN, MBA;

Jagadish Gogate , PhD;

Branislav Mancevski , MD;

Edward S. Kim , MD, FACP, MBA;

03/01/2019

Esketamine Nasal Spray Tolerability Trends During Post-Dose Monitoring in Patients With Treatment-Resistant Depression

Objective: This post hoc analysis assessed (1) whether the first-week incidence of adverse events (AEs) considered most commonly linked to the duration of the post-dose monitoring period ...

Mary Petrillo , PharmD;

Jagadish Gogate , PhD;

H. Lynn Starr , MD, FAAP;

Jennifer Kern Sliwa , PharmD, BCPP;

Ella Daly , MB, BCh, BAO;

David Williamson , PhD, MBA;

Lewis Manera , MS;

03/01/2019

A Phase 3 Non-Inferiority Study Comparing Paliperidone Palmitate 1-Month vs 3-Month Long-Acting Injectables for Negative Symptom Improvement in Schizophrenia

Background: Negative symptoms of schizophrenia are predictors of long-term disability. Paliperidone palmitate 3-month formulation (PP3M) provides a sustained release of paliperidone, perm...

Edward S. Kim , MD, FACP, MBA;

Arun K. Singh , MD, PhD, MCh, MNAMS;

Katalin Pungor , PhD;

Maju Mathews , MD;

Jagadish Gogate , PhD;

Srihari Gopal , MD;

03/01/2019